Jade Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$153.2MTTM through 30 Jun 2026
Free Cash Flow -$123.7MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-34.8%ROE
-32.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio14.93x
Net Debt-$311.3Mnet cash position
Cash & Equivalents$107.3M
Quality Metrics
Altman Z-Score19.03
Piotroski F-Score2 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
Diluted EPS-$1.07TTMFY2025: $-4.06
Dividend
$2.40Per share, FY20250.00%Yield
Capital Allocation
R&D Spend$136.7M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.